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The number of studies highlighting the role of microRNAs (miRNAs) in human physiology and diseases is growing,
but many miRNA-driven regulatory mechanisms remain elusive. A proper understanding of the exact functions of
individual miRNAs and their interaction with specific targets is vitally important because such knowledge might
help cure diseases for which no effective treatment currently exists. Herein, we present current views on the role of
the miRNA-mediated regulation of gene expression in the case of select spinocerebellar ataxias (SCAs) and their
potential involvement in the pathogenesis of these diseases. Specifically, we summarize published data showing
the known links between miRNAs and CAG repeat-dependent SCAs. Moreover, using the example of SCA type 3
(SCA3), we refer to the issue of prediction and validation of miRNA targets, and we demonstrate that miR-181a-1
may regulate the 3′-UTR of the ATXN3 gene.
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Several spinocerebellar ataxias (SCAs) belong to trinu-
cleotide repeat expansion disorders (TREDs), which are
a relatively large group of incurable dominantly inherited
neurological diseases. More specifically, six SCAs belong
to polyglutamine (PolyQ) diseases and are triggered by an
expansion of the glutamine-coding CAG repeat, which is
responsible for polyQ tract formation. A long polyQ
stretch can elicit numerous aberrant cellular processes that
lead to the degeneration and death of neuronal cells.
MicroRNAs (miRNAs) are potent regulators of gene
expression. They act at the post-transcriptional level by
inhibiting protein synthesis that occurs with or without
transcript degradation. It appears that these small RNAs
are engaged in a wide range of physiological and patho-
logical activities in cells; therefore, their function and
contribution to the pathogenesis of SCAs is of special
consideration.Review
This review summarizes the current knowledge regarding
the putative involvement of miRNAs in the pathogenesis
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article, unless otherwise stated.proven associations between specific miRNAs and these
diseases that have been reported. Moreover, it addresses
some aspects of miRNA target prediction and validation
using the example of our own research on the regulation
of the ataxin-3 transcript.Brief characteristics of CAG repeat-dependent SCAs and
miRNA-mediated regulation of gene expression
There are six SCAs (SCA-1, 2, 3, 6, 7, and 17) among
the polyQ diseases [1-3], and their common denominator
is the expression of CAG repeats of abnormal length in
the open reading frame (ORF) of the ataxin (ATXN) genes.
The pathogenic glutamine repeat threshold in most of
these SCAs is approximately 35, except for SCA3 and
SCA6, in which cases the pathogenic repeat range starts
from 50 and 21, respectively. The ataxias that fall under
the category of polyglutamine diseases have similar clinical
presentations; however, molecular studies are necessary to
distinguish particular SCA types. Current views on the
identified molecular processes causing or modulating the
neurodegenerative phenotype in spinocerebellar ataxias
have been discussed recently and reviewed thoroughly [4].
The normal function of the polyglutamine proteins im-
plicated in SCAs seems to be quite disparate and may be
succinctly defined as follows: ataxin-1 and ataxin-7 play a
role in transcription regulation [5-7], ataxin-2 is involvedMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ataxin-3 interacts with transcriptional components and
is responsible for de-ubiquitination and transcription
regulation [10], ataxin-6 is linked to Ca+ signaling/homeo-
stasis [11], and ataxin-17 is linked to general transcription
(TFIID complex) [12] (reviewed in [4]).
The expanded CAGs may trigger pathogenic effects
based on three types of mechanisms: (1) toxic RNA gain-
of-function, (2) toxic protein gain-of-function, or (3) both
transcript and protein loss-of-function [3,13,14]. The toxic
protein gain-of-function mechanism explains neurodegen-
eration as the result of the expression of glutamine-rich
proteins that can misfold and form aggregates, typically in
nuclear inclusions, and eventually result in neuronal dys-
function and loss [15-17]. More recently, however, mutant
CAG repeat transcripts have also been shown to contrib-
ute to the pathogenesis of polyQ diseases. Specifically,
aberrant alternative splicing, transcript nuclear transport
and export, RNA interference, and nucleolar stress result-
ing in apoptosis have been reported to be involved in
CAG repeat RNA toxicity (reviewed in [18,19]).
To date, more than 2,500 mature human miRNAs have
been deposited in the miRNA registry (miRBase, Release
20) [20]. These important molecules are endogenous short
RNAs that downregulate gene expression by imperfect
pairing with complementary sites within transcript se-
quences; miRNAs suppress their targets’ translation, stimu-
late their deadenylation and degradation, or induce target
cleavage (reviewed in [21]). Regarding the canonical bio-
genesis process, human miRNAs are generated by two
RNase III endonucleases (Drosha and Dicer) that act se-
quentially in the nucleus and the cytoplasm (reviewed in
[22-25]). The ribonuclease Drosha, acting together with
the DGCR8 protein within the complex named Micropro-
cessor, cleaves primary miRNA transcripts (pri-miRNA)
into pre-miRNA precursors that are approximately 60
nucleotides long, while the ribonuclease Dicer processes
pre-miRNAs into mature miRNA duplexes that are
approximately 22 nucleotides long. Both canonical and
non-canonical miRNA biogenesis pathways, the assem-
bly of the miRNA-induced silencing complex (miRISC),
and various intricate miRNA-mediated mechanisms of
gene expression regulation have been recently discussed
in detail [26].
Generally, the level of the polyQ-expanded protein is
among the factors that contribute to disease severity
[27-30]; however, the proposed cellular mechanisms that
regulate protein levels remain to be fully characterized.
miRNAs that are the key regulators of protein dosage in
cells must therefore be directly linked with the pathogen-
esis of SCAs. The roles of miRNAs in the development
and regulation of the nervous system and in a wide array
of disorders of the nervous system have been proven in
many studies (reviewed in [31-41]). Several miRNAs havebeen shown to target different neurodegenerative disease-
related proteins and modulate their concentration in cells
(e.g., BACE1, ataxin-1 or α-synuclein in the case of Alz-
heimer’s disease (AD), SCA1 and Parkinson’s disease (PD),
respectively ([42,43] and references therein)). Moreover, it
was demonstrated that the dysfunction of the brain-
enriched miRNAs that specifically target and regulate the
expression of disease-associated genes may lead to neu-
rodegeneration and that disease-related proteins inter-
act with the miRNA machinery [44-46]. Therefore, it is
of growing importance to address the plausible involve-
ment of miRNAs in the pathogenesis of particular SCA
types and to identify the activities of individual miRNAs
on SCA disease-coding genes.
Links between miRNAs and CAG repeat-dependent SCAs
Specific links between miRNA regulation and CAG repeat-
dependent SCAs have been described in several studies
(reviewed in [47]) (Table 1). However, most of hitherto
published reports focus on the role of miRNAs in the most
common SCAs, namely SCA1 and SCA3.
miRNAs in SCA1
A study on SCA1 was the first to reveal that some miRNAs
can regulate the expression of target transcript mRNA con-
taining a CAG repeat expansion. More specifically, that
study showed that miR-19a, miR-101, and miR-130a co-
regulate the 3′-UTR of ATXN1 through the inhibition of
ATXN1 translation [48]. The gene coding for human
ATXN1 has a long 3′-UTR region (approximately 7 kb),
which implies an important role in the post-transcriptional
regulation governed by miRNAs. Moreover, cerebellar de-
generation and ataxia in mice was reported to be intercon-
nected with the impairment of miRNA biogenesis in
Purkinje cells [49]. In a reporter assay, which is the sim-
plest and most straightforward method of validation of
miRNA-mRNA interactions, miRs 19a, 101, and 130a were
shown to downregulate the expression of ATXN1 [48].
Interestingly, miR-101 affected both the mRNA and pro-
tein levels, whereas miR-19a and miR-130a decreased the
protein levels only. Although these miRNAs exerted their
effect in different cell lines when transfected individually, a
markedly stronger effect was observed when miRs 19a, 101
and 130a were transfected together and cooperated in the
regulation of their target. Moreover, inhibiting the en-
dogenous expression of all three miRNAs in HEK293T
cells with specific inhibitors and the mutagenesis of
miRNA target sites in the 3′-UTR of a hATXN1[86Q]
expression vector enhanced the cytotoxicity of the
mutant ATXN1 protein and significantly reduced cell via-
bility. Taken together, these findings show that miRNA-
mediated posttranscriptional regulation of the ATXN1
gene may modulate SCA1-related neuropathology by af-
fecting protein levels.
Table 1 Reported changes in miRNA expression in SCAs and their links with polyQ toxicity
Observed changes miRNA prediction Experimental methods Experimental models Refs.
SCA1
miR-19, −101 and −130
downregulate the ATXN1 gene
Candidate miRNAs were
identified using the PicTar
algorithm.
Transfection with miRNA
duplexes and their specific 2′-
O-methyl inhibitors followed
by western blot and RT-PCR
analyses. miRNAs transfected to




HeLa and NIH3T3 cell lines
[48]
Eight miRNAs were chosen for
further examination based on
the number of target sites in
the ATXN1 transcript and their
neuronal expression. Luciferase reporter assays
(Promega) with vectors
carrying fragments or full
length human ATXN1 3′-UTRs.
HeLa cell line
miRNA levels and their
expression patterns in mouse
cerebella were assessed by
northern blot analysis and in
situ hybridization with LNA
probes (Exiqon).
C57/B6 WT mouse
Cell death assays with mutant
ATXN1deprived of target sites.
HEK293T cell line
miRNA expression upregulated
in SCA1 patients; the increase
more prominent in the cortex
samples





Human cerebellum and cortex,




in SCA1 cerebellum but
strongly induced in the cortex
qRT-PCR, TaqMan miRNA assays
(Applied Biosystems) for miR-
144 and miR-101.
Upregulated miRNAs predicted
to target ATXN1, e.g., miR-101,
-130a, -19a, -302
ATXN1 mRNA and protein




expression, miR-25 does not
affect ATXN1 levels
Overexpression of miRNA
duplexes and miRNA inhibitors




hLuc reporters and miRNA
duplexes or 2′-O-methyl
modified masking oligos. miRs
144 and 101 tested separately
and in combination.
No evidence for a statistically
significant difference in miRNA
expression. A trend to
overexpression of miR-33-5p,
−34-5p and -92a-5p
- Illumina Hi-Seq 2000, small




34 miRNAs upregulated; 14 at
both time points, 15 at the 4-
week time point only and 5 at
the 12-week time point
miRCURY LNA all species
microRNA arrays (Exiqon)
Cerebellar RNA from SCA1 BO5
transgenic mice [82Q] analyzed
at two time points (at 4 and 12
weeks of age)
[53]
Individual miRNAs analyzed by
qRT-PCR with TaqMan assays
(miRs 150, 335, 23a, 24 and
143)
12 miRNAs downregulated; 1
miRNA at both time points, 4
and 7, respectively at the 4-
and 12-week time points only
miR-150 levels increased in
cerebellar Purkinje neurons and
slightly decreased in granule
cells
In situ hybridization using
dig-labeled DNA-LNA probes
(Exiqon)
SCA1 BO5 transgenic mice -
Purkinje neurons, granule cells
A concomitant increase in miR-
150 and decrease in Rgs8 and
Vegfa levels
TargetScan; Rgs8 and Vegfa
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Table 1 Reported changes in miRNA expression in SCAs and their links with polyQ toxicity (Continued)
A dose-dependent decrease in
Vegfa expression induced by
the increased miR-150 activity
Transient transfection with
MirVana miR-150 miRNA
mimics followed by qPCR and
WB. Luciferase assays (Pro-
mega) with wild-type Vegfa-3′
UTR and miR-150 mimic.
Mouse Neuro2A
SCA2
Upregulation of bantam and
miR-12





bantam miRNA is a
downstream modulator/





Drosophila dcr-1 mutants, fly
eyes, HeLa cells with normal
and pathogenic Ataxin-3
treated with siRNA targeting
dicer mRNA
[57]
No evidence for a statistically
significant difference in miRNA
expression. A trend to a
decrease in miR-1-3p and an
increase in miR-100-5p, −33-5p
and 92a-5p levels.
- Illumina Hi-Seq 2000, small




miR-34b is upregulated, and
miR-25, −125b, −29a are
downregulated in SCA3 patients.
Expression of miR-25 and -125b
was associated with the course
of disease.
miRbase, TargetScan and micro.
org were used to search for
miRNA binding sites in the
human ATXN3 3′-UTR
miRCURY LNA human miRNA
Array (Exiqon) (v.14.0),
validation miRNA expression by
qRT-PCR (Applied Biosystems)
Blood samples obtained from




No evidence for a statistically
significant difference in miRNA
expression. A trend to an
increase in miR-33-5p and -92a-
5p levels and a decrease in
miR-375-3p
- Illumina Hi-Seq 2000, small
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miRNAs, especially miR-144, in brain aging and SCA1
pathogenesis has been provided by a genome-wide
microarray analysis [50]. This study revealed a global
age-related miRNA deregulation in the cortex and cere-
bellum of humans, chimpanzees and rhesus macaques.
Interestingly, the vast majority of miRNAs in the exam-
ined samples were downregulated, and only a small frac-
tion of miRNAs were found to be upregulated. A highly
conserved miR-144 was found to be related to the aging
process but regulated differently between species. Its ex-
pression was decreased in the human cortex but was
consistently induced in the aging cerebellum and cortex
of nonhuman primates. Moreover, a subsequent analysis
of human samples showed a widespread activation of
miRNA expression in the cortex and cerebellum of SCA1
patients relative to the miRNA expression in the brains of
healthy individuals. The level of miR-144 that was pre-
dicted to bind to the ATXN1 3′-UTR was elevated in the
cortex. Other miRNAs (e.g., miR-101, −130a, −19a, −302)
predicted to target ATXN1 for degradation were also
found to be upregulated. Next, the potential regulation ofthe ATXN1 transcript by the candidate miRNAs was ex-
amined using miRNA overexpression and inhibition as
well as reporter assays. Of the three miRNAs tested,
miRs 144 and 101 considerably decreased the endogen-
ous ATXN1 protein levels (miR-25 activity was not ob-
served). Similarly, these two miRNAs reduced reporter
gene expression when tested either separately or collect-
ively. Overall, it was concluded that the activation of
specific miRNAs could serve to reduce the cytotoxic ef-
fect of the expanded mutATXN1 and that miRNA de-
regulation may be a risk factor for disease development.
Protective functions for miRNAs have been also pro-
posed by others [33,37,51,52].
Global profiling of miRNA expression in a mouse model
of SCA1 was performed to study alterations in miRNA ex-
pression in the cerebellum at both pre-symptomatic and
symptomatic stages of pathogenesis [53]. More specific-
ally, the analysis revealed changes in the levels of 46 miR-
NAs in BO5 SCA1 transgenic mice [82Q], and a number
of miRNAs displayed altered expression patterns before
the onset of clear phenotypes. Mice were analyzed at two
time points, i.e., 4 and 12 weeks. Of the miRNAs that were
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creased expression; 14 of these miRNAs exhibited in-
creased expression for both time points analyzed, and 15
and 5 exhibited increased expression at only the 4- or 12-
week time points, respectively. In contrast, the miRNA ex-
pression level was decreased for 12 miRNAs, one at both
time points and 4 and 7 at the 4- and 12-week time
points, respectively. Importantly, the observed changes
in miRNA expression (e.g., miR-150 and miR-335) were
found immediately after the start of mutant Atxn1 ex-
pression in SCA1 mice and prior to phenotypic onset,
showing that the deregulation of miRNA expression in
the cerebellum of transgenic mice contributes to the
early pathogenesis of SCA1. Moreover, in line with the
fact that the expression of the mutAtxn1 protein is re-
stricted to cerebellar Purkinje cells in SCA1 transgenic
mice, elevated miR-150 expression was observed select-
ively in Purkinje neurons. In addition, the levels of two
transcripts that are predicted targets of miR-150, Rgs8
and Vegfa, were reduced. The latter target was further
validated in Neuro2A cells using miR-150 mimics and
reporter assays; analyses of both types confirmed the
functionality of binding sites for miR-150 that are
present in Vegfa mRNA. Collectively, these data demon-
strated that the expression levels of mutAtxn1 and miR-
150 together with its target mRNA are highly intercon-
nected. It was proposed that the mutAtxn1 de-represses
activity at miRNA promoters, leading to an increase in
miRNA levels, or acts through yet unknown a gain-of-
toxic function mechanism. Therefore, evidence that
miRNA misregulation during the critical post-natal
period may underlay SCA1 pathogenicity was provided.
Moreover, in this work, a promising therapeutic ap-
proach based on the RNAi-mediated suppression of
mutant Atxn1 was presented. This therapeutic interven-
tion for SCA1 has been developed further by the same
group and described elsewhere [54].
The miRNA deregulation at the beginning of the
pathological process has been also investigated in Dros-
ophila transgenic model of SCA1 with the use of deep
sequencing [55]. Specifically, two RNA samples from
flies and one control were analyzed. The expression of
miRNAs was evaluated at an early stage of the patho-
logical process, 3 days after the induction of toxic
proteins. Many of the selected miRNAs displayed low
expression or highly variable expression between the
tested samples. Although a trend toward the overex-
pression of miR-33, miR-34 and miR-92a was observed,
no evidence for a statistically significant difference in
miRNA expression at this early stage of the disease was
found. Therefore, these results suggest that the toxicity
in SCA1 in the early stages of the pathological process
and the deregulation of miRNA expression most likely
are not related.miRNAs in SCA3
The miRNA bantam (ban) was identified as a down-
stream modulator/suppressor of polyQ toxicity in a
Drosophila model of SCA3 that prevents degeneration
[56]. Upregulation of the ban miRNA suppressed degen-
eration and diminished the toxicity of ataxin-3, which is
the disease-causing protein for SCA3. Suppressing ban
activity was connected with neither a change in the level
of the pathogenic protein nor its accumulation and was
shown to occur downstream of the polyQ protein accu-
mulation. Moreover, reduced miRNA processing due to
the knockout of Dicer1 enhanced the neurodegeneration
induced by ataxin-3 in both flies and human cells by
modulating pathways that normally contribute to polyQ
toxicity [56]. The protective activity due to miRNAs was
found to be specific because siRNA-dependent path-
ways did not modulate polyQ toxicity. Therefore, this
research adds another piece of corroborating evidence
that miRNA pathways dramatically modulate polyQ-
induced neurodegeneration.
A protective role of miRNAs in age-associated processes
and polyQ disorders was further supported by demon-
strating that miR-34b mitigates the toxicity of ataxin-3 in
Drosophila [57]. Specifically, the upregulation of miR-34
in this fly model extended the median lifespan and re-
duced the neurodegeneration induced by human polyQ
disease protein.
Drosophila transgenic model of SCA3 has been also
used to investigate deregulation of miRNA expression
by deep sequencing, as described for SCA1 with re-
gard to the same analysis [55]. The study conducted
at the beginning of the pathological process revealed
a trend toward a decrease in miR-1 and an increase
in miR-33, miR-92a and miR-100 levels, however, the
observed changes in miRNA expression were not sta-
tistically significant.
Most recently, it has been demonstrated that miRNAs
are useful biomarkers for SCA3, as specific changes in
regulatory miRNA levels were identified in the serum ob-
tained from patients suffering from this disease [58]. The
microarray analysis validated by qRT-PCR revealed that
miR-25, miR-125b, miR-29a and miR-34b were differen-
tially expressed in SCA3 patients. Additionally, miR-29a
and miR-34b showed the most dramatic changes in their
expression levels, whereas the expression of miR-25 and
mir-125b was associated with the course of disease. The lat-
ter miRNAs, miRs 25 and 125b, were found to bind to the
3′-UTR of the ATXN3 gene. All miRNAs proposed by Shi
et al. as potential biomarkers were earlier reported to be
connected with neuronal physiology and pathology in
terms of neurodegeneration [59-63]. Moreover, mir-34b
was previously shown to be elevated in the plasma of pre-
manifest Huntington’s disease (HD) patients and predicted
to be a protective factor for HD [60]. These findings, which
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potential value in the diagnosis of patients with neurode-
generative disorders.miRNAs in other CAG repeat-dependent SCAs
The involvement of miRNAs in the pathogenesis of
SCA7 has been investigated in Drosophila transgenic
model of this disease, along with studying their role in
SCA1 and SCA3 [55]. As aforementioned, global profiling
of miRNA expression did not show significant changes in
miRNA levels at an early stage of the pathological process
in the examined SCAs. In the case of SCA7 the level of
miR-33 and miR-92 tended to be higher and the level of
miR-375 was found to be lower but these differences were
not statistically significant. Therefore, no important asso-
ciations between the toxicity induced by the expansion of
CAG repeats in SCA7 and the deregulation of miRNA ex-
pression have been reported.
With regard to other SCA types, the link between neu-
rodegeneration and miRNAs was demonstrated by show-
ing that the gene encoding TATA-binding protein (TBP),
which is mutated in SCA type 17 (SCA17), is downregu-
lated by miR-146a [64]. Finally, some pathogenic proteins,
such as ataxin-2, might be required for miRNA function-
ing; it was shown that the ataxin-2 protein, which inter-
acts with Ago1, impairs the repressive activity of several
miRNAs [65].Figure 1 Potential contribution of miRNAs to the pathogenesis of CA
the CAG expansion in the ATXN genes and CAG expansion-induced toxicity
disease-causing genes. Grey rectangles represent appropriate 3′-UTRs. Their
indicate the number of sites for miRNA families broadly conserved among
6.2) [70]. Green numbers show the number of validated miRNA-target inter
numbers and unbolded ones denote the number of interactions validated
C) Mechanisms of miRNA-mediated control of gene expression. The main r
genes are schematically presented. Additionally, essential methods used foSummary of miRNA-mediated gene regulation in SCAs
All of the above-mentioned findings suggest that miRNA
pathways can modulate polyQ-induced neurodegenera-
tion but that the pathogenesis of polyQ diseases can also
influence miRNA expression. It has been proven that
miRNAs are implicated in the pathogenicity associated
with SCAs at many levels of different pathological pro-
cesses; however, miRNA specific functions remain largely
unknown. Moreover, the question persists, how exactly
miRNAs affect CAG repeat-mediated neurodegeneration
and whether such miRNA activity is similar in all SCA
types. A concept relating miRNAs and ataxias could be
built on the known miRNA mode of action (Figure 1).
The miRNA-mediated regulation of gene expression may
be exerted by different mechanisms (reviewed in [26]),
eventually leading to the reduction in levels of both factors
responsible for the pathogenesis of polyQ diseases, i.e.,
mutant proteins and toxic transcripts [66]. The 3′-UTR
regions of CAG repeat-dependent SCAs vary drastically in
length, which may be important with regard to the fact
that miRNA binding sites are mostly located in 3′-UTRs
of target genes. Although 3′-UTR lengths did not always
correlate with the number of miRNA binding sites, the
ATXN1 3′-UTR being the best-studied in terms of
miRNA-mediated regulation is the longest and contains
the greatest number of predicted miRNA binding sites
[67]. Apart from direct regulation of genes triggering
particular SCAs, miRNA may be also engaged in theG repeat-dependent SCAs. A) The schematic presentation of
factors. B) The graphical presentation of the 3′-UTRs of SCA
length is delineated and a scale of 1,000 nt is shown. Black numbers
vertebrates predicted by the TargetScanHuman algorithm (Release
actions collected in the miRTarBase (Release 4.5) [85]; bold green
by methods providing strong and less strong evidence, respectively.
egulatory activities of miRNAs and global deregulation of multiple
r validation of miRNA-mRNA interactions are listed.
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multiple transcripts and affecting expression of numerous
proteins. All in all, miRNAs regulatory potential contrib-
utes to the pathogenesis of CAG repeat-dependent SCAs.
Prediction and validation of miRNA targets in SCA3
Identifying biologically relevant miRNA targets is of para-
mount importance and involves the reliable prediction of
miRNA-mRNA interactions and the positive validation of
functionality of these interactions. Many different algo-
rithms have been developed to predict miRNA-mRNA
binding; computational tools such as miRANDA [68], Pic-
Tar [69], TargetScan [70], RNAhybrid [71] or PITA [72]
have been successfully used for more than a decade, while
the more recently invented programs miRco [73] and
MREdictor [74] are currently coming into use. Similarly,
various approaches for the experimental verification of
predicted miRNA-mRNA interactions have been reported
to date (reviewed in [75-77]). The most straightforward
method for the verification of miRNA function is a
transfection of cells with miRNA mimics or miRNA in-
hibitors, followed by quantitative analyses of target
mRNA and protein levels [78,79]. There are also various
high-throughput methods, such as the increasingly
popular small RNA deep sequencing and microarrays as
well as proteome and transcriptome analyses, which
allow the identification of thousands of miRNA-target
pairs [80,81]. Moreover, the most advanced and modern
methods are based on UV crosslinking and immunopre-
cipitation followed by deep sequencing and bioinfor-
matic mapping of the reads (reviewed in [82]). The
simplest and most reliable method, however, is the use
of luciferase reporter assays because miRNA activity on
reporter genes can be easily measured [69,83]. Reporter
systems enable the study of single specific miRNA-
mRNA interactions (reviewed in [84]) and have proven
to be convenient and reliable in many studies (data and
references collected in [85]). Therefore, they serve as an
efficient and routinely used strategy for the verification
of individual miRNA-mRNA interactions. More than
4,000 miRNA-target interactions have been validated by
reporter assays, the collection of which is considered to
provide strong experimental evidence accumulated in
the miRTarBase [85,86], which is the database contain-
ing the largest amount of such validated interactions
(51,460 in total).
SCA3 (also known as Machado-Joseph disease) is among
the most common dominantly inherited ataxias [87-89].
The post-transcriptional miRNA-mediated regulation of
the disease-causing ATXN3 expression has been described
only in few reports [55,56,58] (Table 1). In our previous
study, we performed an in-depth computational analysis of
the miRNA interactions with all mRNAs derived from
genes triggering hereditary neurological disorders knownas trinucleotide repeat expansion diseases (TREDs) and
showed that the gene mutated in the case of SCA3 may be
subject to miRNA regulation [67]. From predicted poten-
tial interactions, we selected two for further experimental
verification using a reporter system. Specifically, we have
preliminarily validated a putative regulation of the ataxin-3
transcript by two miRNAs, miR-9-2 and miR-181a-1, by
employing a luciferase assay and a set of reporter con-
structs as described previously [90,91]. Briefly, synthetic
oligonucleotides corresponding to sequences of single
binding sites (b.s.) for the appropriate miRNAs (ATXN3 b.
s. for miR-9-2 and miR-181a-1) were cloned into the pmir-
GLO Dual-Luciferase miRNA Target Expression Vector
(Promega). This vector, which was specially designed for
miRNA-mRNA interaction studies, is based on Promega
dual-luciferase technology, with firefly luciferase (luc2) as
the primary reporter for monitoring mRNA regulation and
Renilla luciferase (hRluc-neo) as a control reporter for
normalization. Typically, in a reporter system, three types
of constructs are prepared; a wild-type (WT) construct
bearing an intact binding site(s) for the studied miRNA, a
construct with mutations in its binding site(s) (MUT), and
a perfect match (PM) construct (Figure 2A). Mutations in
the sequence corresponding to the miRNA seed disrupt
the native pairing within the binding region of the candi-
date miRNAs, which provides a negative control, whereas
perfect complementarity with miRNA sequences induces
target degradation and provides a positive control.
To validate the interactions between our candidate miR-
NAs, miR-9-2 and miR-181a-1, and the ATXN3 tran-
script, we transfected HEK293T cells with either reporter
carrying potential miRNA binding sites. Four constructs
were transfected into cells and tested in parallel. These
constructs were co-transfected with appropriate miRNA-
coding plasmid vectors (System Biosciences) because our
experimental system required miRNA overexpression.
The transient transfection of cells with reporter constructs
was followed by measuring the reporter activity, which en-
abled the validation of predicted miRNA-mRNA interac-
tions. Specifically, we obtained considerable repression of
the luciferase expression after the transfection of reporter
constructs for miR-181a-1, whereas no repression was
measured after the transfection of reporters for miR-9-2
(Figure 2B).
The reduction in luciferase activity in the case of the
WT construct carrying b.s. for miR-181a-1 was reprodu-
cible and statistically significant (suppression to 64%).
The PM construct repressed luciferase to a very low
level, while the luciferase activity for the MUT construct
showed efficient de-repression. In contrast, we did not
observe any decrease in luciferase activity when the WT
construct carrying b.s. for miR-9-2 was transfected to
cells. As for the experimental procedures, enzymatic ac-
tivities of firefly and Renilla luciferases were measured
Figure 2 Validation of the interaction between miRNAs and mRNAs. A) Schematic representation of the standard reporter constructs used
for the experimental validation of miRNA-mRNA interactions. WT, MUT and PM denote appropriate constructs; a construct bearing a wild-type
potential binding site for the studied miRNA (WT), a construct with mutated binding site (MUT), and a construct with full complementarity (PM).
B). Regulation of the ataxin-3 transcript by miR-9-2 and miR-181a-1. Relative repression of luciferase expression for both miRNAs is shown. The
standard errors were calculated from independent experiments. The asterisk indicates statistical significance (p value < 0.05).
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substrates and procedures from the Dual Luciferase
Assay Kit (Promega). The values for firefly luciferase ac-
tivity for every reporter construct were normalized to
the corresponding values of Renilla luciferase activity to
account for varying transfection efficiency. Relative ex-
pression values for all constructs were obtained by com-
paring their normalized luciferase activities with those of
the control plasmid. Transfection was repeated 6 and 8
times for miR-9-2 and miR-181a-1, respectively.
Overall, using the luciferase reporter system, we have
validated the interaction between miR-181a-1 and the
3′-UTR of ATXN3 mRNA positively and the interaction
between miR-9-2 and the 3′-UTR of ATXN3 mRNA nega-
tively. This is only a preliminary validation of miRNA-
mRNA interactions with respect to SCA3 and needs to be
elaborated farther, and it is an example of the utility of the
reporter system in the search for miRNA targets. Never-
theless, this is the first evidence for the direct binding of
miR-181a-1 to the 3′-UTR of the human ATXN3 gene.
Conclusions
Many studies have shown that miRNAs play a crucial
role in the development and functional regulation of the
nervous system, and the deregulation of miRNAs was
postulated and proved in numerous neurological disor-
ders of different etiology, including TREDs and even
strictly polyQ diseases (reviewed in [47]). Modest but
significant changes in miRNA expression were shown to
influence severity and/or disease progression. Hence, the
deregulation of miRNA expression is now being consid-
ered a hallmark of many diseases that has both prognos-
tic and diagnostic value. All studies performed on the
CAG repeat-dependent SCAs demonstrate changes in
miRNA expression patterns in these disorders and, most
importantly, suggest that miRNA pathways and polyQ-induced neurodegeneration are interdependent processes.
There is accumulating evidence that miRNAs are import-
ant contributors to the pathogenicity associated with
SCAs. Therefore, close attention should be paid to the
therapeutic potential of miRNAs due to their regulatory
activities. Both the miRNA-based therapy (e.g., the use of
miRNA mimics, artificial miRNAs, miRNA inhibitors and
sponges) as well as the implementation of miRNA-based
biomarkers would be beneficial in the treatment of all
SCAs. Moreover, in terms of therapy for these diseases
particularly important is the fact that miRNAs may re-
press the levels of both toxicity factors, namely polyQ
protein and mutant CAG repeat transcript. Of all the
CAG repeat-dependent SCA types studied to date, how-
ever, most findings are related to SCA1 and, secondarily,
to SCA3. The role of miRNAs in the pathogenesis
of other CAG repeat-dependent SCAs and miRNA-
specific functions remain largely unknown and require
further investigation.Competing interests
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